Absci vs Medvolt (2026)
Absci and Medvolt both apply generative AI to drug discovery for pharmaceutical partners, and CB Insights lists Medvolt among Absci's top competitors. They differ in scale and in what a partner receives. Absci is a clinical stage antibody company: Origin-1 designs antibodies against chosen epitopes, a wet lab of more than 77,000 square feet tests them, and ABS-201 is in a Phase 1/2a trial, with Eli Lilly a strategic investor. Medvolt, based in Pune, India, sells MedGraph, an in silico platform of modules for drug repurposing, small molecule design, knowledge graphs and free energy simulation, as software and as delivered projects, and its services extend to antibody humanization, bispecific design and peptides. It runs five preclinical programs of its own. Absci suits a partner that wants antibodies designed and tested in a laboratory; Medvolt suits a team that wants computational discovery across modalities from a platform positioned as affordable.
- Laboratory testing of every design, at billions of measurements a week.
- An antibody in Phase 1/2a trials.
- A peer reviewed 2026 method paper with a stated success rate.
- Security testing by third parties described in an annual report.
- Software modules a client can run in the cloud or on premises.
- Small molecules, peptides, antibodies, oligonucleotides and enzymes on one platform.
- Knowledge graph and literature curation services.
- A modular platform sold as software or as delivered projects.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Absci and Medvolt are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Absci | Medvolt |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2011 | Not recorded |
| Headquarters | Vancouver, Washington | Pune, India |
| Website | absci.com | medvolt.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached.
Absci designs antibodies with generative AI and proves them in its own laboratory, from de novo design with Origin-1 through lead optimization, and develops them as medicines, led by ABS-201 for pattern hair loss.
Source: AI Health Index, October 2026
Medvolt offers MedGraph, an AI and physics based discovery platform with modules for repurposing, new chemical entities, knowledge graphs and binding affinity, sold to pharma and biotech as software or as projects its scientists deliver.
Source: AI Health Index, October 2026
Questions buyers ask
What does a partner receive?
Medvolt delivers software modules or in silico results from projects run by its scientists. Absci delivers designed antibodies that its laboratory has made and tested. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 12, 2026. No vendor pays for placement.
Which modalities does each cover?
Absci works on antibodies. Medvolt covers small molecules, peptides, antibodies, oligonucleotides and enzymes. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 12, 2026. No vendor pays for placement.
What proof of performance does each offer?
Absci reports interim clinical data for ABS-201 and a peer reviewed paper with a measured model success rate. Medvolt reports time, cost and risk reductions without a source or named client. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 12, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Medvolt Tech Private Limited is a privately held Indian company; Absci is listed on Nasdaq.